Dmitri Shalin Interview with Angelo A. Alonzo about Erving Goffman entitled I asked Goffman If He Had Time and He Said “No” But If I Wanted to Talk as He Ran a Couple of Errands on Telegraph Ave I Was Welcome to Come Along

Dr. Angelo A. Alonzo, professor of sociology at the Ohio State University and Yale University, wrote this memoir for the Erving Goffman Archives at the request of Dmitri Shalin and approved posting the present version on the web

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

An analytic typology of disclaimers, excuses and justifications surrounding illness: A situational approach to health and illness

An analytic typology of disclaimers, excuses and justifications is developed to demonstrate how illness is possible within our everyday social situations. Beginning with the concepts of the 'disclaimer' from Hewitt and Stokes, and the 'exuce' and 'justification' from Scott and Lyman, these concepts are extended and reconceptualized to apply to circumstances where signs and symptoms of illness compromise and disrupt role performance and situational participation. Using a situational perspective on health and illness, the presentation of a disclaimer, excuse or justification is seen as a means of allowing the symptomatic individual to 'drift' in and out of illness while protecting his and others' social identity, the integrity of the social situation and the individual's health status.

Health behavior: Issues, contradictions and dilemmas

American medicine faces many contradictions and dilemmas. This is especially the case with regard to preventive health behavior. This paper explores the effects of several issues, contradictions and dilemmas on the American experience with primary preventive health behavior. These issues include: individualism, victim blaming, therapeutic nihilism, the over abundance of health information, America as a culture of risk takers, and the dilemma of the jungle vs the zoo. Four types of health behavior are defined. The first type of health behavior is the primary prevention of disease, defect, injury or disability. The second type is detection of asymptomatic disease, injury and defect. Third, is the promotion of enhanced levels of health, wellness and quality of life. And the fourth, at a mote societal level, protective behaviors to make environmental transactions safe from disease, injury, defect and disability. These four types of health behavior are each explored in relation to societal values, technology and economics to determine which of these facilitate or impede health behavior at both the individual and societal levels.health behavior prevention detection promotion protection

The impact of the family and lay others on care-seeking during life-threatening episodes of suspected coronary artery disease,

To understand the impact of the family on care-seeking during a suspected episode of acute coronary artery disease (CAD) interviews were conducted with 1102 individuals hospitalized for a suspected myocardial infarction. Analyzing the care-seeking behavior of these individuals within life threatening illness behavior and situational perspectives, bivariate and multivariate analyses revealed that family members, especially a spouse, had both positive and negative influences on the duration of time between acute symptom onset and arrival at a hospital emergency room. To reduce both the morbid and mortal consequences of acute CAD it is recommended that we direct our intervention efforts toward warning the public of situational circumstances which contribute to extended self treatment and evaluation during acute episodes of CAD.crisis coping family illness behavior myocardial infarction

Health as situational adaption: A social psychological perspective

A model to encompass the complex relationship between the individual and his social, physical and cultural environments and to provide strategies for intervention has not yet been developed. While professionals acknowledge the importance of an ecological and holistic conception of man-environment interaction, various biases and ideologies prevent them from adequately taking this interaction into account. To overcome this inadequacy this paper explores a relational conception of health, the central importance of the socially defined situation for health and adaption, the limits of medicine and holism in intervening in problems of adaption and suggests a situational approach to the study of health and adaption. By stressing the socially defined situation and the social psychological actor it may be possible to sensitize the actor to socially situated man-environment transactions, to preserve the actor's confidence in his own health, to encourage individual responsibility for maintaining health and to promote an awareness of signs and symptoms that require medical attention. Within a larger framework, however, it is not effective to intervene in the individual's social situations if we do not also attempt to alter the macro economic, political, cultural and structural elements in society which encourage, produce and support unhealthy environmental conditions.

The structure of emotions during acute myocardial infarction: A model of coping

The present state of medical care for heart attacks, or acute myocardial infarction (AMI), clearly indicates that rapidly and expeditiously seeking definitive medical care will reduce morbidity and prevent mortality. Despite the clearly established advantages of rapid AMI treatment, the time from the onset of acute symptoms of AMI to definitive medical care is often prolonged and individuals with a prior history of AMI and/or coronary artery disease (CAD) extend care-seeking. Behaviors and actions surrounding acute care-seeking are often fraught with complex social, psychological and emotional processes. The purpose of the present paper is to bring together a theoretical and an applied understanding of the interval of time from acute symptom onset to definitive medical care during AMI; and to understand the role of emotions in the care-seeking process. This task is especially important among individuals with a prior history of AMI and/or CHD. These individuals can be seen as experiencing a "spectrum of posttraumatic disturbances", ranging from anxiety to posttraumatic stress disorder and alexithymia. These disturbances contribute to extended care-seeking thereby placing the individuals at greater risk for AMI and sudden cardiac death. Effective intervention requires three elements. First, knowledge is necessary so that individual and lay others can correctly label symptoms and signs of an AMI. Second, it is necessary to provide feasible behaviors that individuals and lay others can use to access definitive medical care. Third, and perhaps most importantly, it is necessary to provide understanding of and skills to cope with the emotional arousal surrounding both the primary traumatic experience of symptoms and signs, potential secondary traumatic consequences of AMI care-seeking and tertiary trauma from the long-term consequences of CHD.care-seeking acute myocardial infarction coping thrombolytic therapy

Causes of delay in seeking treatment for heart attack symptoms

With the advent of thrombolytic therapy and other coronary reperfusion strategies, rapid identification and treatment of acute myocardial infarction greatly reduces mortality. Unfortunately, many patients delay seeking medical care and miss the benefits afforded by recent advances in treatment. Studies have shown that the median time from onset of symptoms to seeking care ranges from 2 to 61/2 hours, while optimal benefit is derived during the first hour from symptom onset. The phenomenon of delay by AMI patients and those around them needs to be understood prior to the design of education and counseling strategies to reduce delay. In this article the literature is reviewed and variables that increase patient delay are identified. A theoretical model based on the health belief model, a self regulation model of illness cognition, and interactionist role theory is proposed to explain the response of an individual to the signs and symptoms of acute myocardial infarction. Finally, recommendations are made for future research.delay acute myocardial infarction